Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Vomiting 2Uterine Cervical Neoplasms 2Nausea 2Condylomata Acuminata 2Breast Neoplasms 2Sezary Syndrome 1Renal Insufficiency 1Osteoarthritis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Kidney Failure, Chronic 1Cancer Pain 1Bone Neoplasms 1Adenomatous Polyposis Coli 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15Vaccines, Synthetic 10Papillomavirus Vaccines 7Vaccines 5Imiquimod 4Trichloroacetic Acid 3Gels 3human papillomavirus vaccine, L1 type 16, 18 2green tea extract polyphenone E 2Podophyllin 2Human Papillomavirus Recombinant Vaccine nonavalent 2Ethanol 2Duration of Therapy 2Cryotherapy 2Cantharidin 2ranpirnase 1polyphenon E 1nanocurcumin 1hecolin 1berdazimer sodium 1Zinc 1Viusid 1Vaccination 1VP-102 1Tuberculin 1Therapies, Investigational 1Tea 1Surgical Procedures, Operative 1PRA1 protein, Candida albicans 1Omiganan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Condylomata Acuminata × Duration of Therapy × Clear all
NCT00092482 2017-03-22

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 3 Completed
3,882 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00517309 2017-03-22

FUTURE

Merck Sharp & Dohme LLC

Phase 3 Completed
1,877 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

Data powered by HemOnc (CC BY 4.0) Colophon âš¡